首发精神分裂症患者实施帕利哌酮治疗的临床效果评价

Evaluation of the Clinical Effect of Paley Piperidone Treatment in First Episode Schizophrenic Patients

目的分析首发精神分裂症患者实施帕利哌酮治疗的临床效果。方法选择本院2016年1月—2017年10月收治63例首发精神分裂症患者作为研究对象,将其分为研究组(32例)与对照组(31例)。研究组采用帕利哌酮实施治疗,对照组采用利培酮治疗,分析两组患者的治疗效果。结果研究组PANSS总分为(46.69±6.01)分,低于对照组的(71.10±7.35)分,差异具有统计学意义(P<0.05);PSP对照组为(38.80±8.87)分,低于研究组的(54.40±8.93)分,差异具有统计学意义(P<0.05)。结论首发精神分裂症患者应用帕利哌酮治疗临床效果良好,可使患者社会功能得以有效改善。

Objective To analyze the clinical effect of parripidone in patients with first-episode schizophrenia.Methods From January 2016 to October 2017,63 cases of first-episode schizophrenics were selected as the research subjects.They were divided into study group(32 cases)and control group(31 cases).The study group was treated with Paley piperidone.The control group was treated with risperidone.The treatment effect of two groups of patients was analyzed.Results The total score of PANSS in the study group was(46.69±6.01)points.Compared with the control group(71.10±7.35)points,the difference was statistically significant(P<0.05);the PSP control group was(38.80±8.87)points.Compared with the study group(54.40±8.93)points,the difference was statistically significant(P<0.05).Conclusion The application of parripidone in patients with first-episode schizophrenic patients has a good clinical effect,which can effectively improve the social function of patients.